Study of Tarceva and Targretin in Stage I-II Lung Cancer

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Dartmouth-Hitchcock Medical Center
Study ID
NCT00125372
Status
Completed

Conditions

  • Carcinoma, Non-small-cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Key Dates

First listed
Aug 1, 2005
Start date
Dec 31, 2005
Status verified
Dec 2018
Primary completion
Aug 31, 2010
Completion
Aug 31, 2010

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib and Bexarotene
    Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.

Primary Outcome Measure

Number of Participants With Change in Expression Level of EGFR. [ Time Frame: Baseline and 9 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Norris Cotton Cancer CenterLebanonNew Hampshire03756-

Find similar trials in Lebanon, NH

By research site
Norris Cotton Cancer Center· Lebanon, NH

Related Studies